Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer

Novel covalent inhibitors of KRAS(G12C) have shown limited response rates in patients with KRAS(G12C)-mutant (MT) colorectal cancer. Thus, novel KRAS(G12C) inhibitor combination strategies that can achieve deep and durable responses are needed. Small-molecule KRAS(G12C) inhibitors AZ’1569 and AZ’803...

Descripción completa

Detalles Bibliográficos
Autores principales: Khawaja, Hajrah, Briggs, Rebecca, Latimer, Cheryl H., Rassel, Mustasin, Griffin, Daryl, Hanson, Lyndsey, Bardelli, Alberto, Di Nicolantonio, Frederica, McDade, Simon S., Scott, Christopher J., Lambe, Shauna, Maurya, Manisha, Lindner, Andreas U., Prehn, Jochen H.M., Sousa, Jose, Winnington, Chris, LaBonte, Melissa J., Ross, Sarah, Van Schaeybroeck, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Targeting Drug Resistance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808374/
https://www.ncbi.nlm.nih.gov/pubmed/36279564
http://dx.doi.org/10.1158/1535-7163.MCT-22-0301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808374/
https://www.ncbi.nlm.nih.gov/pubmed/36279564
http://dx.doi.org/10.1158/1535-7163.MCT-22-0301

Ejemplares similares